TSMC Shares Hit Record High as Goldman Sachs Raises Price Target on AI Demand Outlook 
Samsung to Double AI-Powered Mobile Devices with Google Gemini in Global AI Race 
L3Harris Nears $500M Deal to Sell Majority Stake in Space Propulsion Portfolio to AE Industrial 
Grok AI Faces Global Scrutiny Over Safeguard Failures and Illegal Content on X 
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
U.S. Airline Flight Cancellations Surge After Venezuela Military Operation and FAA Airspace Closures 
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
NextEra Energy Stock Rises After Reaffirming Earnings and Dividend Growth Outlook 
Tokyo Electric Power Shares Surge as Kashiwazaki-Kariwa Nuclear Reactor Restart Nears 
Saks Global Enterprises Seeks $1 Billion Loan Amid Possible Chapter 11 Bankruptcy Filing 
Chinese EV Stocks Slide as December Sales Growth Slows, Raising Demand Concerns 
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing 
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Bain Capital Moves to Acquire Majority Stake in Echo Marketing 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
NEW YORK, March 31, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of CTI BioPharma Corp. (“CTI BioPharma”) (NASDAQ:CTIC) pursuant or traceable to the Registration Statement and Prospectus issued in connection with the September 24, 2015 Public Offering and/or between March 4, 2014 and February 9, 2016.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of New York. To get more information go to: http://zlk.9nl.com/cti-biopharma.
The complaint alleges that the documents filed in connection with the offering contained materially false and misleading statements and/or omissions, including: (1) the detrimental effect on survival of experimental treatment pacritinib; (2) that the Company’s clinical trials demonstrated deaths associated with pacritinib usage; (3) that the Company’s new drug application for pacritinib would likely be withdrawn; (4) that, as such, the Company’s future revenues were impaired; and (5) that the company lacked adequate internal controls.
On February 8, 2016, it was revealed that the FDA had placed a partial hold on clinical studies of pacritinib, citing “identified…fatal and life-threatening safety issues in pacritinib-treated patients…”
If you suffered a loss in CTI BioPharma you have until April 11, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/cti-biopharma.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
